Tandem Diabetes Care, based in San Diego, focuses on products for insulin-dependent diabetes, employing 2,400 staff since its IPO in 2013. Its advanced insulin pumps, including the t:slim X2, feature Control-IQ technology and are compatible with various CGM sensors.
TNDM has been in the news recently: In the past three months, 13 analysts have assessed Tandem Diabetes Care (NASDAQ:TNDM), presenting a spectrum of opinions. Additionally, both the Rosen Law Firm and the Schall Law Firm are investigating the company for potential securities claims related to misleading information and malfunctioning insulin pumps, which contributed to a 19.9% decline in its stock price.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.